Loic L.
- Country
- France
- Department
- Departament oncologie
Research Overview
- Phase 1 Study of SHP2 Inhibitor BBP-398 and KRAS-G12C Inhibitor Sotorasib in Advanced Solid Tumors with KRAS-G12C Mutation
- Phase I Evaluation of MEDI5752 Combined with Stereotactic Radiotherapy in Metastatic Soft Tissue Sarcoma Patients
- Phase I Study of OKI-219 Monotherapy and in Combination with Endocrine or HER2-Targeted Therapy in Advanced Solid Tumors and Breast Cancer
Data & Insights
Has run more than one trial at 98 of 212 partner sites.
Specializations
Advanced Solid Tumors
The investigator specializes in treating advanced and metastatic solid tumors, with particular attention to tumors exhibiting specific genetic mutations including KRAS G12C mutations and HER2 mutations.
- Genetic-targeted therapies
- Novel therapeutic combinations
- Immunotherapy approaches
Research focuses on developing treatment strategies for patients with advanced solid tumors who have progressed after standard treatments.
Gastrointestinal Oncology
Expertise in treating gastrointestinal stromal tumors (GIST) and exploring innovative therapeutic approaches for patients with unresectable or metastatic disease.
- Targeted therapy combinations
- Treatment resistance mechanisms
- Advanced GIST management
Investigation of novel drug combinations including immunotherapy agents for gastrointestinal malignancies.
Precision Medicine
Focus on molecular-guided treatment approaches targeting specific genetic alterations, including FGFR mutations and other actionable genetic markers.
- Biomarker-driven therapy
- Molecular profiling
- Personalized treatment strategies
Development of targeted therapies for rare and treatment-resistant cancers based on genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.